title: Hepatosplenic αβ T-cell lymphoma with myelodysplastic syndrome.
abstract: We describe a patient with hepatosplenic 33 T-cell lymphoma who showed pancytopenia and myelodysplasia. A 35-year-old man was admitted with fever, pancytopenia, and hepatosplenomegaly but with no lymphadenopathy. We also found trilineage myelodysplasia in the bone marrow on his first admission. The patient had high fever and anemia but no evidence of infection and was tentatively treated with prednisolone. This treatment resulted in a transient improvement of the cytopenia and a reduction of spleen size. However, 10 months after the first manifestation, progression of the splenomegaly and fever became apparent, and a splenectomy was performed. The pathologic findings for the spleen showed diffuse and disseminated infiltration of medium- to large-sized T-lymphocytes in the splenic red pulp. These cells were immunohistochemically positive for CD3, CD5, CD7, CD8, CD16, CD56,T-cell receptor 33 (TCR33),T-cell intracellular antigen 1, and granzyme B but were negative for CD4, CD30, CD57, and TCR33. These data suggested a diagnosis of hepatosplenic 33 T-cell lymphoma. A Southern blot analysis revealed gene rearrangement of the TCR 3-chain gene but not the immunoglobulin heavy chain gene in the spleen cells. An in situ hybridization analysis for the Epstein-Barr virus revealed negative results. The patient received 8 courses of combination chemotherapy and achieved a partial remission; however, the dysplastic features of the marrow cells persisted after the partial remission was obtained. Additional treatment with allogeneic bone marrow transplantation resulted in a transient complete remission; however, the patient relapsed 11 months later. Because he had experienced no lymphadenopathy and showed dysplastic features in the bone marrow, the diagnosis was highly dependent on the pathologic findings for the resected spleen.
authors.affiliation: First Department of Internal Medicine, Tokyo Medical University, Japan. t-tom@venus.dti.ne.jp
authors.forename: Tomoiku
authors.initials: T
authors.lastname: Takaku
authors.forename: Keisuke
authors.initials: K
authors.lastname: Miyazawa
authors.forename: Goro
authors.initials: G
authors.lastname: Sashida
authors.forename: Nahoko
authors.initials: N
authors.lastname: Shoji
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimamoto
authors.forename: Noritake
authors.initials: N
authors.lastname: Yamaguchi
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Ito
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Mukai
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ohyashiki
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000378:metabolism; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D013160:Splenic Neoplasms / Q000150:complications / Q000378:metabolism / Q000473:pathology*
chemical_list: D015703:Antigens, CD; D016693:Receptors, Antigen, T-Cell, alpha-beta